title: Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.
abstract: Glucagon-like peptide-1 receptor agonist (GLP-1RAs) labels warn about acute pancreatitis (AP) and impose upon doctors the obligation to inform patients about symptoms of AP. Here we systematically reviewed the risk of AP in randomized placebo-controlled trials (RCTs) investigating the effect of GLP-1RAs in type 2 diabetes. We performed a systematic review with meta-analysis of long-term (minimum 24 months), placebo-controlled GLP-1RA RCTs in which AP was a predefined adverse event and adjudicated by blinded and independent adjudicating committees. Three high-quality RCTs included a total of 9347 GLP-1RA-treated and 9353 placebo-treated patients with type 2 diabetes. Compared to placebo, treatment with GLP1-RA was not associated with increased risk of AP (Peto odds ratio 0.745 [95% CI, 0.47-1.17]). Trial Sequential Analysis suggested that additional evidence is needed. In conclusion, this review found no evidence that treatment with GLP-1RA increases the risk of AP in patients with type 2 diabetes.
authors.affiliation: Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
authors.forename: Heidi
authors.initials: H
authors.lastname: Storgaard
authors.affiliation: Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
authors.forename: Frederik
authors.initials: F
authors.lastname: Cold
authors.affiliation: Gastrounit, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.|Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Lise L
authors.initials: LL
authors.lastname: Gluud
authors.affiliation: Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.|Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Tina
authors.initials: T
authors.lastname: Vilsbøll
authors.affiliation: Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.|Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.|The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Filip K
authors.identifier: 0000-0002-2495-5034
authors.initials: FK
authors.lastname: Knop
mesh_terms: D000208:Acute Disease; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004763:Glucagon-Like Peptides / Q000009:adverse effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D000069450:Liraglutide / Q000009:adverse effects; D016017:Odds Ratio; D010195:Pancreatitis / Q000139:chemically induced*; D010455:Peptides / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D000097789:Glucagon-Like Peptide-1 Receptor Agonists; D000099194:Semaglutide; D000067758:Glucagon-Like Peptide-2 Receptor
chemical_list: D004763:Glucagon-Like Peptides; D007004:Hypoglycemic Agents; D000069450:Liraglutide; D010455:Peptides; D000097789:Glucagon-Like Peptide-1 Receptor Agonists; D000099194:Semaglutide; C479460:lixisenatide; D000067758:Glucagon-Like Peptide-2 Receptor
keywords: 
  GLP-1 analogue; antidiabetic drug; incretin therapy; liraglutide; meta-analysis; type 2 diabetes